(Q46427740)

22 December 2017

title

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials (English)

1 reference

22 December 2017

1 reference

1 reference

Diane D Wang

1

1 reference

22 December 2017

Shuzhong Zhang

2

1 reference

22 December 2017

Hong Zhao

3

1 reference

22 December 2017

Angela Y Men

4

1 reference

22 December 2017

Kourosh Parivar

5

1 reference

22 December 2017

publication date

20 July 2009

1 reference

22 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

22 December 2017

volume

49

1 reference

22 December 2017

issue

9

1 reference

22 December 2017

page(s)

1012-1024

1 reference

22 December 2017

Body surface area as a determinant of pharmacokinetics and drug dosing

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Drug interactions in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

What is the effect of adjusting epirubicin doses for body surface area?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337512

21 January 2018

Identifiers

DOI

10.1177/0091270009337512

1 reference

22 December 2017

1 reference

22 December 2017